242 related articles for article (PubMed ID: 28620887)
1. Controlled Suspensions Enable Rapid Determinations of Intrinsic Dissolution Rate and Apparent Solubility of Poorly Water-Soluble Compounds.
Andersson SBE; Alvebratt C; Bergström CAS
Pharm Res; 2017 Sep; 34(9):1805-1816. PubMed ID: 28620887
[TBL] [Abstract][Full Text] [Related]
2. Interlaboratory Validation of Small-Scale Solubility and Dissolution Measurements of Poorly Water-Soluble Drugs.
Andersson SBE; Alvebratt C; Bevernage J; Bonneau D; da Costa Mathews C; Dattani R; Edueng K; He Y; Holm R; Madsen C; Müller T; Muenster U; Müllertz A; Ojala K; Rades T; Sieger P; Bergström CAS
J Pharm Sci; 2016 Sep; 105(9):2864-2872. PubMed ID: 27112289
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic Dissolution Rate Profiling of Poorly Water-Soluble Compounds in Biorelevant Dissolution Media.
Teleki A; Nylander O; Bergström CAS
Pharmaceutics; 2020 May; 12(6):. PubMed ID: 32481718
[TBL] [Abstract][Full Text] [Related]
4. Ethanol effects on apparent solubility of poorly soluble drugs in simulated intestinal fluid.
Fagerberg JH; Al-Tikriti Y; Ragnarsson G; Bergström CA
Mol Pharm; 2012 Jul; 9(7):1942-52. PubMed ID: 22651218
[TBL] [Abstract][Full Text] [Related]
5. The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs.
Schwebel HJ; van Hoogevest P; Leigh ML; Kuentz M
Pharm Dev Technol; 2011 Jun; 16(3):278-86. PubMed ID: 20214530
[TBL] [Abstract][Full Text] [Related]
6. An interlaboratory investigation of intrinsic dissolution rate determination using surface dissolution.
Etherson K; Dunn C; Matthews W; Pamelund H; Barragat C; Sanderson N; Izumi T; Mathews CDC; Halbert G; Wilson C; McAllister M; Mann J; Østergaard J; Butler J; Khadra I
Eur J Pharm Biopharm; 2020 May; 150():24-32. PubMed ID: 32061919
[TBL] [Abstract][Full Text] [Related]
7. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability.
Zakeri-Milani P; Barzegar-Jalali M; Azimi M; Valizadeh H
Eur J Pharm Biopharm; 2009 Sep; 73(1):102-6. PubMed ID: 19442726
[TBL] [Abstract][Full Text] [Related]
8. Intestinal solubility and absorption of poorly water soluble compounds: predictions, challenges and solutions.
Fagerberg JH; Bergström CA
Ther Deliv; 2015; 6(8):935-59. PubMed ID: 26316058
[TBL] [Abstract][Full Text] [Related]
9. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs.
Jinno J; Kamada N; Miyake M; Yamada K; Mukai T; Odomi M; Toguchi H; Liversidge GG; Higaki K; Kimura T
J Control Release; 2006 Mar; 111(1-2):56-64. PubMed ID: 16410029
[TBL] [Abstract][Full Text] [Related]
10. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media.
Fagerberg JH; Tsinman O; Sun N; Tsinman K; Avdeef A; Bergström CA
Mol Pharm; 2010 Oct; 7(5):1419-30. PubMed ID: 20507160
[TBL] [Abstract][Full Text] [Related]
11. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
12. Concomitant intake of alcohol may increase the absorption of poorly soluble drugs.
Fagerberg JH; Sjögren E; Bergström CAS
Eur J Pharm Sci; 2015 Jan; 67():12-20. PubMed ID: 25444841
[TBL] [Abstract][Full Text] [Related]
13. Dissolution behavior of various drugs in different FaSSIF versions.
Klumpp L; Leigh M; Dressman J
Eur J Pharm Sci; 2020 Jan; 142():105138. PubMed ID: 31704344
[TBL] [Abstract][Full Text] [Related]
14. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
15. Improving Dissolution Rate of Carbamazepine-Glutaric Acid Cocrystal Through Solubilization by Excess Coformer.
Yamashita H; Sun CC
Pharm Res; 2017 Dec; 35(1):4. PubMed ID: 29288433
[TBL] [Abstract][Full Text] [Related]
16. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
[TBL] [Abstract][Full Text] [Related]
17. Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound.
Frank KJ; Westedt U; Rosenblatt KM; Hölig P; Rosenberg J; Mägerlein M; Brandl M; Fricker G
Eur J Pharm Sci; 2012 Aug; 47(1):16-20. PubMed ID: 22579958
[TBL] [Abstract][Full Text] [Related]
18. Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3.
Fuchs A; Leigh M; Kloefer B; Dressman JB
Eur J Pharm Biopharm; 2015 Aug; 94():229-40. PubMed ID: 26032292
[TBL] [Abstract][Full Text] [Related]
19. Model for Long Acting Injectables (Depot Formulation) Based on Pharmacokinetics and Physical Chemical Properties.
Shah JC; Hong J
AAPS J; 2022 Mar; 24(3):44. PubMed ID: 35298711
[TBL] [Abstract][Full Text] [Related]
20. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective.
van Hoogevest P; Liu X; Fahr A
Expert Opin Drug Deliv; 2011 Nov; 8(11):1481-500. PubMed ID: 21895540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
